

## Product End-of-Life Policy

Cohance Lifesciences Limited is committed to managing the end of life (EoL) of its products in an environmentally responsible, safe, and legally compliant manner. This policy ensures that product disposal, recovery, and recycling processes are conducted in accordance with applicable laws, ISO standards, and industry best practices.

### Our Commitment:

- ❖ Comply with all applicable environmental laws, regulations, and end-of-life (EoL) requirements, ensuring that products nearing the end of their life are managed in a legally responsible manner.
- ❖ Promote responsible and efficient handling of products at the end of their lifecycle, by setting clear procedures for their identification, safe management, and proper processing.
- ❖ Encourage reuse, refurbishment, dismantling, and certified recycling of products and their parts wherever feasible, to reduce environmental impact and support resource recovery.
- ❖ Ensure secure data erasure for electronic devices, using recognized and standard-compliant methods such as those outlined by the National Institute of Standards and Technology (NIST), to protect sensitive information.
- ❖ Work with qualified downstream vendors for recycling, reuse, or final disposal activities, ensuring they meet compliance standards and follow safe practices.
- ❖ Identify EoL indicators such as reduced demand, outdated technology, or product phase-out plans, and take timely actions to manage product end-of-life responsibly.
- ❖ Communicate clearly with customers about return options, disposal instructions, and available alternatives, to make the EoL process transparent and user-friendly.
- ❖ Avoid unsafe or non-compliant disposal of products, especially when handling hazardous waste, and ensure that no product or part is exported or imported in violation of environmental or trade regulations.

This policy applies to all products manufactured or distributed by Cohance Lifesciences Limited, including branded/unbranded goods, returns, defective components, and internal surplus. The policy is reviewed every three years or earlier, if significant changes occur. It is the responsibility of the Management and Employees to implement this policy. The policy is communicated to stakeholders and displayed at all operational sites.

Date: 12.08.2025

REV. No: 01



**Dr. Prasada Raju V**  
Managing Director

**Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.  
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.  
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | Company Email: [info@suvenpharm.com](mailto:info@suvenpharm.com)

